Presentations highlighted the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL (sublingual cyclobenzaprine HCl) Dr. Lederman continued, “There remains a significant ...

What is TNX-102 SL? TNX-102 SL is a non-opioid, centrally acting analgesic designed for managing fibromyalgia. When is the PDUFA goal date for TNX-102 SL? The FDA has set the PDUFA goal date for ...

TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL is FDA-approved for the treatment of fibromyalgia CHATHAM, N.J., Sept. 18, ...

Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) and posttraumatic stress disorder ...

Bedtime TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in the Phase 3 RESILIENT study resulted in statistically significant improvement in the primary endpoint of fibromyalgia nociplastic pain ...

We are excited to advance TNX-102 SL and look forward to evaluating its potential as a new treatment option for those affected by depression.” The IND clearance enables Tonix to proceed with the ...

NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health ...

Presentations highlighted the proprietary formulation technology and pharmacokinetic properties of TNX-102 SL (sublingual cyclobenzaprine HCl) Composition and methods patents based on the eutectic ...